As of October 21, there were more than 200 public funds in the list of the top ten circulating shareholders of 91 listed companies that disclosed the third quarter report in the first batch, with a total of 222400 shares, corresponding to the stock market value of 50.11 billion yuan. Up to now, the most favored companies are Asahi tech, Sinopharm, Sinopharm, and Sinopharm.
According to the third quarter report released by sannuo biology, the growth value of Ruiyuan managed by Fu Pengbo increased by 2.8168 million shares in the third quarter; the balanced value of Ruiyuan managed by Zhao Feng increased by 2.6158 million shares. At the end of the third quarter, the two Ruiyuan funds held 41.8261 million shares of sannuo bio, with a corresponding market value of 1.674 billion yuan, ranking the fourth and fifth largest circulating shareholders of the shares. Since becoming the top ten circulating shareholders of sannuo bio in the fourth quarter of 2019, Ruiyuan has increased its position for three consecutive quarters. In the first quarter of this year, Ruiyuans equilibrium value became the top ten circulating shareholders of the stock, and continuously increased its position in the following two quarters. However, there are also differences in the layout of the public offering fund. Boshi healthcare industry, which is managed by GE Chen, has reduced its position on the stock in the third quarter.
Xingquan Heyi and Xingquan Herun funds, headed by Xie Zhiyu, increased their holdings of Jianyou shares by 8.2913 million shares in the third quarter, corresponding to the stock market value of 887 million yuan. Xingquan Heyi also increased its holding of 2.462 million shares of Huahai pharmaceutical in the third quarter, with the corresponding stock market value increasing to 581 million yuan. In addition, Xingquan Heyi also reduced its holding of 2.12 million shares of Shengnong development in the third quarter, with the corresponding stock market value falling to 142 million yuan.
Zhu Shaoxing, the star fund manager of Wells Fargo, which has a reputation of managing only one fund in one life, has also attracted investors attention. After sorting out the relevant data, the reporter of Securities Daily found that after adding 6.0993 million shares of Zhifei biology in the third quarter, the shares of Fuguo Tianhui fund managed by Zhu Shaoxing increased to 11 million shares, corresponding to the stock market value of 1.532 billion yuan. In the third quarter of the third quarter, Ruiyuan also increased its position in the chemical stock real horse technology, holding 11.6931 million shares, corresponding to the market value of 204 million yuan, ranking the eighth largest circulating shareholder.
The investment style of Feng Mingyuan, the star fund manager of Cinda Australia Bank fund, often makes the market incomprehensible. According to the third quarter report, the fund reduced its holdings of 1.57 million shares and 3.36 million shares of Changying precision and Red Star Development in the third quarter of this year, and the corresponding stock market value dropped to 173 million yuan and 9.1436 million yuan.
Public offering favors Pro cyclical plate
Pharmaceutical and biological industry is favored
Continuing the characteristics of heavy positions of public funds at the end of the second quarter of this year, as of the data disclosed so far, the holding amount of public funds in the pharmaceutical and biological sector in the third quarter is still the largest. Among the public fund stocks that have been exposed, 16 pharmaceutical and biological industry stocks have been held by the fund. In addition to Zhifei biology and Jianfan biology which have been held by public funds, Sanyou medical, Shanhe pharmacy, Pumen technology, Jianmin group and other stocks are still held by several public funds in the third quarter, but the overall number of positions has declined.
Wu Xingwu, fund manager of the strategic investment department of Guangfa fund, pointed out that there was a certain range of adjustment in the earlier stage of the year. On the one hand, the cumulative increase in the first eight months of this year was relatively large, and the valuation was at a historical high level; on the other hand, due to the recent tightening of market liquidity than in previous months, resulting in a certain degree of callback in the pharmaceutical sector.
Source of this article: Ren Hui, editor in charge of Securities Daily_ NBJ9607